C. R. Bard, Inc. announced that it has received Pre-Market Approval (PMA) to market the LifeStent FlexStar and FlexStar XL Vascular Stent Systems from the US FDA. The devices are approved for the treatment of occlusive disease in native superficial femoral arteries (SFA) and proximal popliteal arteries, and are marketed by the Bard Peripheral Vascular Division, located in Arizona. Two-year clinical data on the LifeStent vascular stent demonstrated a freedom from target lesion revascularization rate of 78% vs. 42% (p